Other PHGDH inhibitors, NCT‐502 and NCT‐503 reduce the production of glucose‐derived serine in breast cancer and suppress the growth of PHGDH‐dependent cancer cells in culture and in orthotopic xenograft tumors [98]. Here, PHGDH is linked to cancer.